{"transactions":[{"id":710122,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Restricted stock Units","published_at":"2026-07-14T20:00:20.000Z","date":"2026-07-10","kind":"grant","planned":false,"acquired":true,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On July 10, 2026, the reporting person was granted 1,500 restricted stock units (\"RSUs\"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting."}],"balance_after":1500,"derivative":{"exercise_price":0,"underlying":"Series A Preferred Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001493152-26-033167","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226033167/ownership.xml","form_type":"4"}},{"id":731126,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock","published_at":"2026-06-22T20:30:18.000Z","date":"2026-06-22","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":0.05,"value":1000.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05."},{"field":"deemedExecutionDate","element":"deemedExecutionDate","label":"F1","text":"On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05."}],"balance_after":378837,"source":{"system":"sec-edgar","filing":"0001493152-26-029594","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315226029594/ownership.xml","form_type":"4"}},{"id":2632513,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Options","published_at":"2021-07-16T21:37:37.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":698256,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on date of grant."}],"balance_after":698256,"derivative":{"exercise_price":0.1626,"exercise_date":"2021-07-08","expiration_date":"2031-07-08","underlying":"Common Stock","underlying_shares":698256},"source":{"system":"sec-edgar","filing":"0001493152-21-017104","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017104/ownership.xml","form_type":"4"}},{"id":2632512,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2021-07-16T21:37:37.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":298837,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant."}],"balance_after":358837,"source":{"system":"sec-edgar","filing":"0001493152-21-017104","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315221017104/ownership.xml","form_type":"4"}},{"id":2968835,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":8220,"price":0.19,"value":1561.8,"ownership":{"direct":true},"balance_after":60000,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":2968834,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-23","kind":"purchase","acquired":true,"shares":20088,"price":0.19,"value":3816.72,"ownership":{"direct":true},"balance_after":51780,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":2968833,"issuer":{"id":7822,"kind":"organization","name":"Oncotelic Therapeutics, Inc."},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2020-11-24T22:30:34.000Z","date":"2020-11-20","kind":"purchase","acquired":true,"shares":31692,"price":0.195,"value":6179.94,"ownership":{"direct":true},"balance_after":31692,"source":{"system":"sec-edgar","filing":"0001493152-20-022450","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/908259/000149315220022450/ownership.xml","form_type":"4"}},{"id":4190531,"issuer":{"id":127789,"kind":"organization","name":"Adhera Therapeutics, Inc.","symbol":"ATRX"},"owners":[{"id":30642,"kind":"person","name":"Shah Amit B.","position":1,"cik":"0001719077","reported_name":"Shah Amit B.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Options to purchase common stock","published_at":"2017-10-06T14:55:44.000Z","date":"2017-10-02","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":60000,"derivative":{"exercise_price":2.7,"exercise_date":"2018-10-02","expiration_date":"2022-10-02","underlying":"common stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001719077-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/737207/000171907717000002/primary_doc.xml","form_type":"4"}}]}